LimmaTech Biologics acquires licence option for AbVacc vaccine LBT-SA7
Under the agreement, Schlieren-based LimmaTech Biologics AG receives the exclusive rights from Abbvacc Inc, a recent spin-out from Integrated...
Innate immunity merger raises €75m
Dutch Oxitope and Norwegian Arxx announced their merger to form Calluna Pharma Inc with the goal to develop therapies for inflammatory and fibrotic...
Novo Nordisk Foundation in US$25m partnership with CARB-X
The Novo Nordisk Foundation is committing up to US$25m to support the early-stage development of drugs, vaccines and diagnostics to prevent,...
AstraZeneca buys Chinese Gracell Biotechnologies for $1.2bn
Pharmaceutical giant Astrazeneca with CEO Pascal Soriot wants to take over the Chinese company Gracell Biotechnologies in order to strengthen its...
Pierre Fabre SAS in US$31m licence deal with Kinnate Biopharma Inc
With the US$31m agreement Pierre Fabre licences the global rights to exarafenib and other pan-RAF program assets from Kinnate...
Researcher find potential target for atherosclerosis
Researchers have found a new way to reverse atherosclerotic plaque formation at the early stages. In Nature Cardiovascular Research, Alma...
Novo Nordisk to acquire Cardior Pharmaceuticals
The take-over agreement includes Cardior’s lead compound CDR132L, currently in Phase II clinical development for the treatment of heart failure....